en · de · es · fr · pt
compound-index.peptides3081.com › Guide › Background And Structural Identity — Hands-On Walkthrough

Background And Structural Identity — Hands-On Walkthrough

By Editorial Desk · published 2025-09-02 · last reviewed 2025-10-05 · Guide

A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Receptor Mechanism and Secretagogue Action

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with C-terminal amide
Average massApproximately 711.9 DaValue derived from the formula
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and aqueous acetonitrileDissolution aided by acidic diluents
Common synonymsIpamorelin; NNC 26-0161Code name used in early reports

背景与分子特征

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

Related pages on this site

Ipamorelin Background and Mechanism

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Background from the literature

== Security cooperation == The agreement aligns with simultaneous U.S.–Pakistan counterterrorism collaboration: the U.S. designated the Balochistan Liberation Army (BLA) as a terrorist organization, a move lauded by Karachi and carried out amid discussions surrounding the trade accord.

It was difficult to obtain a stable crystal of dopamine β-hydroxylase. Hence an homology model based on the primary sequence and comparison to PHM is available. However, a crystal structure was also put forward in 2016.

== History == In 2018, three unrelated children who had similar symptoms of developmental delays, skeletal abnormalities, and mild dysmorphic facial features. The first patient had an autism diagnosis and mild skeletal abnormalities but was otherwise normal. The second patient had poor growth in infancy, difficulty walking, tremors, difficulty speaking, and needed to be homeschooled due to academic difficulties. The third patient had microcephaly, poor growth, and was slow to learn how to walk but was able to attend mainstream school. All three of these patients had a variety of dysmorphic facial features that none of the patients shared except for a prominent nose, wide mouth, and thin upper lip. They were identified as having a de novo mutation on their QRICH1 gene. In 2019, 2 unrelated children were identified as having VERBAS and were found to have subtle chondrodysplasia. In 2021, Fohrenbach et al. described 4 unrelated patients with VERBAS. One patient, a three-year-old, developed nephroblastoma and died from complications, suggesting that increased cancer risk may be a part of the syndrome. In 2023, a 17-year-old girl was suffering from seizures and leukodystrophy. The girl had a history of minor developmental delays and was thought to have a perinatal brain injury resulting in mild right-side paresis. Her mother shared similar dysmorphic facial features, short stature, and distractable nature, causing them to be referred to a genecist. It was discovered that they both carried a novel QRICH1-related mutation and were diagnosed with VERBRAS.

Sources: en.wikipedia.org

Reference notes

==== Combination drugs ==== Butalbital/acetaminophen (Butapap) – combination of butalbital (GABAA receptor positive allosteric modulator and barbiturate) and acetaminophen (analgesic) Ergotamine/caffeine (Cafergot) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline) and caffeine (adenosine receptor antagonist) Ergotamine/chlorcyclizine/caffeine (Anervan) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline), chlorcyclizine (antihistamine and other actions), and caffeine (adenosine receptor antagonist) Meloxicam/rizatriptan (AXS-07; Symbravo) – combination of meloxicam (COX inhibitor/NSAID) and rizatriptan (triptan) [139] Naproxen sodium/sumatriptan (MT-400; SumaRT/Nap; Suvexx; Trexima; Treximet) – combination of naproxen (COX inhibitor/NSAID) and sumatriptan (triptan) – migraine [140] Paracetamol/codeine/buclizine (Migraleve Yellow) – combination of paracetamol (analgesic) and codeine (opioid) Paracetamol/codeine/buclizine (Migraleve Pink) – combination of paracetamol (analgesic), codeine (opioid), and buclizine (antihistamine and other actions) Paracetamol/dichloralphenazone/isometheptene (Amidrine) – combination of paracetamol (analgesic), dichloralphenazone (phenazone (COX inhibitor/NSAID) and chloral hydrate (GABAA receptor positive allosteric modulator)), and isometheptene (adrenergic receptor agonist) Paracetamol/metoclopramide (Paramax) – combination of paracetamol (analgesic) and metoclopramide (various actions) Sumatriptan/naproxen (Treximet) – combination of sumatriptan (triptan) and naproxen (COX inhibitor/NSAID)

=== Bektashism under Ottoman rule === The Bektashis acquired political importance in the 15th century when the order dominated the Janissary Corps. The branch became widespread in the Ottoman Empire, with its lodges scattered throughout Anatolia and the Balkans. It became the official order of the Janissaries, the elite infantry corps of the Ottoman military. Therefore, they also became mainly associated with Anatolian and Balkan Muslims of Eastern Orthodox convert origin, mainly Albanians and northern Greeks (although most leading Bektashi babas were of southern Albanian origin). In 1826, the Bektashi order was banned throughout the Ottoman Empire by Sultan Mahmud II for having close ties with the Janissary corps. Many Bektashi dervishes were exiled, and some were executed, while tekkes were destroyed and their revenues were confiscated. This decision was supported by the Sunni religious elite and the leaders of other, more orthodox, Sufi orders. Bektashis slowly regained freedom with the coming of the Tanzimat In the Balkans, the Bektashi order had a considerable influence on the Islamization of many areas, primarily Albania and Bulgaria, as well as parts of Macedonia, particularly among Ottoman-era Greek Muslims from western Greek Macedonia such as the Vallahades. By the 18th century, Bektashism began to gain a considerable hold over southern Albania and northwestern Greece (Epirus and western Greek Macedonia).

=== In popular culture === The town's name was used in the 1977 Ian Dury song, "Billericay Dickie". The town is described as the Essex location for the BBC TV sitcom Gavin & Stacey, as the home of Gavin Shipman and his parents; however, the filming for scenes actually took place in Wales, including in the town of Dinas Powys in the Vale of Glamorgan.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Has ipamorelin been approved for clinical use?

It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.

Why is selectivity emphasised in the literature?

Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

Network